The Takeover Panel has delivered a rare public criticism of three firms involved in a deal relating to the mining company formerly known as Bumi, five years after its ill-fated debut on the London stock market.
The Panel singled out Credit Suisse, Freshfields and Holman Fenwick Willan for three main breaches of the Takeover Code. The conduct of the firms “was sufficiently serious to merit the issue by the Panel of a statement of public censure”, it said.
A fourth adviser, JP Morgan, failed to satisfy two terms of the code, in conduct the Panel described as “disappointing”, but escaped public censure.
A public criticism is the Takeover Panel’s highest level of censure. It is only the second time in five years the Panel has issued this type of statement.
Bumi was renamed Asia Resource Minerals in 2013 and left the stock market this year after losing more than 90pc of its value. Nat Rothschild, the financier who helped found the firm, once described the venture as “a terrible mistake”.
The acquisition in question dates back to 2011, when Mr Rothschild’s shell company Vallar bought interests in two Indonesian coal mines from Bakrie Group and Bukit Mutiara for $3bn. Vallar later became Bumi, and later still Asia Resource Minerals, in a protracted series of wrangles between Mr Rothschild and his Indonesian partners.
Full content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas